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ABSTRACT
Objective: The present study was designed to determine the neuroprotective effect of Abelmoschus esculentus L. on alloxan-induced diabetic 
neuropathy in rats.
Methods: Diabetes was induced in rats with a single intraperitoneal injection of alloxan monohydrate (130 mg/kg b.w). The ethanol extract of 
A. esculentus L. at a dose of 100 and 200 mg/kg of body weight was administered at single dose per day to alloxan-induced diabetic rats for 21 days. 
The fasting blood glucose was screened in the intermittent on day 0, day 14, and day 21. Behavioral tests such as thermal hyperalgesia test and rotarod 
performance test were performed to assess the thermal sensitivity and muscle grip strength. At the end of the study period, experimental animals 
were sacrificed and sciatic nerve tissues were obtained for histopathological investigation.
Results: Animals treated with A. esculentus L. extarct at a dose of 200 mg/kg of body weight significantly reduced (p<0.05) in hyperglycemia and 
thermal hyperalgesia and significantly increased (p<0.05) in rotarod performance. The sciatic nerve fiber of diabetic rats receiving 200 mg/kg of body 
weight of A. esculentus L. extract also shows no swelling of nerve fibers, and lesser demyelination was observed.
Conclusion: These findings demonstrate that A. esculentus L. exhibits significant antidiabetic and neuroprotective effect against alloxan-induced 
diabetic neuropathy in rats.
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INTRODUCTION
Diabetes mellitus is a condition where body either does not produce 
enough insulin or response to insulin. According to the International 
Diabetes Foundation, in 2014, there were 3.3 million cases of diabetes 
in Malaysia. The prevalence of diabetes in adults between 20 and 
79 years was 16.61% in 2015. The cost per person with diabetes was 
565.35 USD [1].
Diabetes mellitus is best known as a multifactorial metabolic disorder 
characterized by chronic hyperglycemia with abnormal carbohydrate, 
protein, and fat metabolism due to deficiency of insulin or failure of 
body response to insulin or both [2]. Long-term exposure of organ to 
hyperglycemia could lead to chronic complication such as microvascular 
and macrovascular complications. Examples of microvascular diseases 
of diabetes are diabetic retinopathy, diabetic neuropathy, and diabetic 
nephropathy while macrovascular disease is atherosclerosis. In 
short term, acute complications cause clinical manifestation such as 
polydipsia, polyuria, glycosuria, and polyphagia [3].
Diabetic neuropathy is defined as the presence of signs and symptoms 
of nerve fiber dysfunction in people with chronic hyperglycemia [4]. 
Approximately 50% of patients with long-standing type 1 and type 2 
diabetes mellitus have developed diabetic neuropathy. In fact, diabetic 
neuropathy is likely to affect 23 million of 472 million patients 
with diabetes by 2030 [5]. It may be classified as polyneuropathy, 
mononeuropathy, and autonomic neuropathy. The risk factors are long 
duration hyperglycemia, poor control of glucose in blood, smoking, 
heavy alcohol intake, hypertension, and elevated triglycerides [6].
The diabetic neuropathy is due to the background of hyperglycemia, 
so investigation on the pathophysiology of diabetic neuropathy is 
mainly concerned [7]. The pathogenesis of diabetic neuropathy is not 
fully understood, but a number of theories can be described [8]. One 
of the important factors associated with diabetes mellitus is oxidative 
stress [7]. The oxidative stress is due to free radical production 
responded from activation of polyol pathway, advanced glycation end 
products, hexosamine, and diacylglycerol/protein kinase C [9,10].
The Abelmoschus esculentus L. aka Okra or lady’s finger is a flowering 
plant in the mallow family [11]. Okra immature fruits can be taken as 
vegetables or can be used with soup, salads, fresh or dried, fried, or boiled 
[12]. Okra is a powerhouse of valuable nutrients. Approximate half of 
it is soluble fibers in the form of gums and pectins while the rest are 
insoluble fibers, proteins, carbohydrates, minerals, and vitamins. Okra 
is also best known as antioxidant vegetable and has very good benefit 
on cardiovascular disease, Type 2 diabetes mellitus, digestive disease, 
and some cancer [13]. The medicinal values of Okra were revealed and 
reported to have properties on reducing blood glucose, lowering blood 
lipid, and neuroprotection [14,15]. This research is undertaken to 
investigate in vivo antioxidant and antidiabetic activity of Okra as well as 
its neuroprotection effects in alloxan-induced diabetic rats.
METHODS
Plant materials
7 kg of A. esculentus L. (Okra) was obtained from Pasar Besar Klang 
located in Klang which is in the state of Selangor, Malaysia. The plant 
material was identified by a resident botanist through comparison with 
specimen A. esculentus L. kept at the Forest Research Institute Malaysia.
Experimental animals
Male Sprague Dawley albino rats (150–200 g) were used to assess 
in this experiment. The animals were kept and maintained under 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11s3.30023
Research Article
3rd International Conference on Pharmacy and Pharmaceutical Science 2018
Asian J Pharm Clin Res, Vol 11, Special issue 3, 2018
 Yang et al. 
 3rd International Conference on Pharmacy and Pharmaceutical Science 2018 29
standard laboratory conditions (temperature [22°C±2°C] and humidity 
[45°C±5°C]) with 12:12 h day:night cycle. The animals were fed with 
standard laboratory diet and allowed to drink water. Studies were carried 
out in accordance with the Institutional Ethical Guidelines for the care 
of laboratory animals of Management and Science University, Malaysia.
Development of diabetes mellitus model in rats
The rats are fasted overnight. Diabetes is induced by intraperitoneal 
(i.p.) injection of alloxan monohydrate at a dose of 150 mg/kg body 
weight in 0.1 M cold citrate buffer (pH 4.5). To prevent alloxan-induced 
hypoglycemia, 10% dextrose solution is given to rats after 6 h of alloxan 
administration for next 24 h. Induction of diabetes is verified after 72 h 
by measuring blood glucose levels with strips using glucometer, and 
the animals are allowed 14 days for the stabilization of blood glucose 
level. If the blood glucose in rats has higher than 250 mg/L after day 14, 
animals are considered diabetic and used in experiment [16].
Preparation of A. esculentus L. extract
The A. esculentus L. is dried in the hot air oven at 60°C. The dried okra 
is made into fine powders using a blender. The fine powders will be 
extracted in 95% ethanol solvent using Soxhlet extraction method. 
Sequential extractions are performed. The extract (AeL extract) is 
evaporated at 60°C in a rotary evaporator. The remaining extract is 
dried in room temperature for several days to ensure the removal of 
any residual solvent [17].
Treatment of AeL extract to Alloxan-induced diabetic rat (positive 
vs. negative control)
Animals are divided into five groups, and each group consisted of 6 rats. 
The grouping details are follows:
•	 Group	I	-	Normal/control	animals	received	1%	tween	80,	3	ml/kg	
body weight per orally.
•	 Group	 II	 -	Alloxan-induced	diabetic	 rats	 received	1%	 tween	80,	
3 ml/kg body weight per orally.
•	 Group	 III	 -	Alloxan-induced	diabetic	 rats	 received	glibenclamide	
5 mg/kg.
•	 Group	V	 -	 Alloxan-induced	diabetic	 rats	 received	 okra	 extract	
100 mg/kg dissolved in 1% Tween-80.
•	 Group	VI	 -	Alloxan-induced	diabetic	 rats	 received	okra	 extract	
200 mg/kg dissolved in 1% Tween-80.
Each group of rats is fed and observed for 30 days. After 30 days, the 
blood glucose level of each group of rats is determined with strips using 
glucometer and recorded [18].
Behavioral investigation
Thermal hyperalgesia test
Neuropathic pain is evaluated using Eddy’s hot plate, which is an 
instrument designed by Eddy et al. to assess thermal sensitivity. 
The plate was preheated and each of the rats is put on the hot plate 
at fixed temperature of 55°C, and the rat was placed on the hot plate 
and nociceptive threshold, with respect to licking of the hind paw 
or jumping, was recorded in seconds. The cutoff time of 20 s was 
maintained [19].
Rotarod performance test
Rotarod performance test is used to evaluate balance and sensory-motor 
coordination of the subjects. The speed is accelerated to 40 rpm/min. The 
falling time of each rat from rotating spindle was recorded during 5 min period. 
Mean change in the locomotor activity was recorded for each group [20].
Histological and morphological study of sciatic nerve
The rat is anesthetized using ketamine, i.p. injection, 70 mg/kg. 
According to Suri et al., 2002, and Martins et al., 2005, rat is placed 
in prone position and sciatic nerve is exposed at the dorsocaudal 
region. An incision is made strating 0.5 cm laterally from the animal’s 
midline and extending laterally for 3 cm toward the tibiofemoral 
articulation. The femoral biceps and gluteus muscles are separated 
using blunt dissection to allow access to provide exposure of the 
sciatic nerve. Then, the nerve is fixed in situ for 20 min with 4% 
glutaraldehyde in 0.1 M of phosphate-buffered saline at pH 7.4. 
The sciatic nerve is cut from the sciatic notch to the knee level and 
immersed in 2.5% glutaraldehyde in 0.1 M phosphate buffer solution 
at pH 7.4 for overnight. Then, approximately 3 mm lengths of sciatic 
nerve are cut and post-fixed for 2 h in 1% buffered osmium tetroxide 
and dehydrated in graded concentrations of acetone and embedded 
in epoxy resin. A thin layer of transverse section of sciatic nerve 
is cut using blade and stained with 1% toluidine blue and observe 
under a light microscope. The morphological changes of sciatic nerve 
between normal control group, diabetes- induced, and treatment rats 
are observed.
Statistical analysis
Significance of differences between the mean values was determined 
by	the	analysis	of	variance	(ANOVA),	followed	by	Dunnett’s	test.	SPSS	
24, USA, was used for statistical analysis. Graphs were prepared using 
GraphPad Prism 7. Results were considered statistically significant 
when the P < 0.05.
RESULTS
Induction of diabetes
Of total 45 rats that were induced, 10 of them dead due to severe high 
blood glucose and 5 of them were failed to become diabetes before the 
treatment was given.
Effects of okra extracts on blood glucose level in alloxan-induced 
diabetic rats
Thermal hyperalgesia test [Tables 1-3]Graph 1: Histological and morphological study of sciatic nerve
Table 1: Effect of daily oral administration of extracts on blood glucose level of alloxan-induced diabetic rats
Treatment groups Fasting blood glucose (mmol/L)
Day 0 Day 14 Day 21
Normal control 6.00±0.63 5.92±0.41 6.28±0.77
Diabetic control 14.07±1.89 12.95±2.25 14.75±1.76
Diabetic control with glibenclamide (5 mg/kg) 15.27±1.46 10.81±0.88 9.85±0.92*
Diabetic control with Okra extract (100 mg/kg) 12.40±1.36 11.23±1.22 10.63±0.84
Diabetic control with Okra extract (200 mg/kg) 13.75±0.87 10.75±1.58 9.27±0.91*
Values	are	given	as	mean±S.E.M	for	6	rats	in	each	group	(n=6).	*p<0.05=glibenclamide	and	200mg/kg	compared	with	diabetic	control.	S.E.M:	Standard	error	of	the	mean
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Rotarod performance test
Fig. 3a shows the normal control group of sciatic nerve. Fig. 3b shows 
sciatic nerve fiber of diabetic control group. There is obvious edema 
around the epineurium and leakage and infiltration of neutrophils 
around blood vessels, and swelling of nerve fibers (red arrow) was 
observed. Fig. 3c shows the sciatic nerve fiber of diabetic rats receiving 
glibenclamide (5 mg/kg). There are no obvious edema and infiltration of 
neutrophils into the nerve fiber bundle peaks, and no fiber swelling and 
demyelination were observed. Fig. 3d shows sciatic nerve fiber of diabetic 
rats receiving okra extract (100 mg/kg). Swelling of nerve fibers (red 
arrow) was observed, and partial demyelination was seen. Fig. 3e shows 
sciatic nerve fiber of diabetic rats receiving okra extract (200 mg/kg). No 
swelling of nerve fibers and lesser demyelination were observed.
DISCUSSION
In this study, A. esculentus L. extract was given as neuroprotection of 
sciatic nerve in alloxan-induced diabetic rats. Alloxan gain popularity 
to induce type-1 diabetes in rodents which resembles to human insulin 
dependent diabetes mellitus. Alloxan has its property of diabetogenicity 
by reacting with two-SH groups in the sugar binding site of glucokinase, 
resulting in the formation of the disulfide bond and inactivation of the 
enzyme. Glucokinase inhibition reduces glucose oxidation and ATP 
generation that further suppresses glucose-induced insulin secretion. 
In addition, alloxan also inhibits the biosynthesis of insulin through the 
same mechanism [21].
At day 0, a marked rise in fasting blood glucose level was observed in 
alloxan-treated groups as compared to normal group. At day 14, there are 
no significant differences between the treatment groups (glibenclamide 
5 mg/kg and okra extract 100 mg/kg and 200 mg/kg) compared to 
diabetic control, whereas, at day 21, treatment with glibenclamide and 
okra extract 200mg/kg caused significant reduction (p<0.05) in the 
levels of fasting blood glucose compared with diabetic control. 32.6% 
reduction in fasting blood glucose from day 0 to day (Fig. 1). Thus, okra 
extract at dose of 200 mg/kg had demonstrated antiglycemic activity in 
alloxan-induced diabetic rats. The antiglycemic effect of A. esculentus L. 
may due to isoquercetin and quercetin-3-O-beta-glucopyranosyl-(1”’--> 
6”)-glucoside isolated from the okra seed extract and was selectivity 
inhibited rat intestinal maltase and sucrose.
In first behavioral examination, diabetic rats were shown significant 
reduction in paw withdrawal latency compared with normal control 
rats, shown in Fig. 2, indicating that the diabetic rats decreased in 
nociceptive threshold to heat, resulting hyperalgesia. Other than that 
diabetic rats treated with A. esculentus L. extract in 200 mg/kg were 
shown significant reduction (p<0.05) in paw withdrawal latency 
compared with diabetic control rats. Thus, 200 mg/kg A. esculentus L. 
extract shows neuroprotection effect on alloxan-induced diabetic rats.
In second behavioral examination, diabetic rats were shown significant 
reduction in Rotarod performance compared with normal control rats 
(Graph 1), indicating a decrease in muscle grip strength of legs due to 
impairment of sciatic nerve. Other than that, diabetic rats treated with 
A. esculentus L. extract in 200 mg/kg were shown significant reduction 
(p<0.05) in Rotarod performance compared with diabetic control rats. 
Thus, 200 mg/kg A. esculentus L. extract shows neuroprotection effect 
on alloxan-induced diabetic rats.
As the most common complications of diabetes, diabetic neuropathy 
is characterized by the signs and symptoms of nerve fiber dysfunction 
in people with chronic hyperglycemia [4]. In this study, we further 
evaluated the role of A. esculentus L. extraction diabetic neuropathy 
Table 2: Effect of Abelmoschus esculentus L. extract on rats 
subjected to paw heat-hyperalgesia test
Treatment groups Reaction 
time (s)




Diabetic control with glibenclamide (5 mg/kg) 12.24±0.70*
Diabetic control with okra extract (100 mg/kg) 9.74±0.42
Diabetic control with okra extract (200 mg/kg) 12.46±0.71*
Values	are	given	as	mean±S.E.M	for	6	rats	in	each	group	(n=6).	ap<0.05=diabetic	
control	compared	with	normal	control	*p<0.05=glibenclamide	and	OE	
100 mg/kg compared with diabetic control. S.E.M: Standard error of the mean
Table 3: Effect of Abelmoschus esculentus L. extract on rats 
subjected to motor coordination test




Diabetic control with glibenclamide (5 mg/kg) 25.05±3.24*
Diabetic control with okra extract (100 mg/kg) 17.15±1.95
Diabetic control with okra extract (200 mg/kg) 23.08±1.58*
Values	are	given	as	mean±S.E.M	for	6	rats	in	each	group	(n=6).	ap<0.05=diabetic	
control	compared	with	normal	control,	whereas	*p<0.05=glibenclamide	and	OE	
100 mg/kg compared with diabetic control. S.E.M: Standard error of the mean
Fig. 1: Effect of Abelmoschus esculentus L. extracts on fasting 
blood glucose concentration of alloxan-induced diabetic rats
Fig. 2: Effect of Abelmoschus esculentus L. extracts on rats 
subjected to paw heat-hyperalgesia test
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in rat, and our morphological study of sciatic nerve revealed that 
administration of A. esculentus L. extract, especially at dose of 
200 mg/kg, shows no swelling in nerve fibers and lesser extent of 
demyelination to close to the control group.
Therefore, dose dependence of 200 mg/kg body weight of A. esculentus 
L. extract was proposed its antidiabetic and neuroprotective effect 
whereby it exerts a substantial protective effect against alloxan-induced 
diabetic neuropathy in sciatic nerve of rats.
CONCLUSION
The present study has shown that dose dependence of 200mg/kg of the 
extract of A. esculentus L. has attenuated the alloxan-induced diabetic 
neuropathy in rats, whereas 100 mg/kg did not. These effects may be 
indirectly attributed to its potential anti-hyperglycemia properties. 
Which is causing a total 32.6% reduction in fasting blood glucose. 
These findings provide a therapeutic potential for future treatment of 
diabetic neuropathy. However, further studies are required to elucidate 
the mechanism of neuroprotection of A. esculentus L. on sciatic nerve. 
Besides,	the	treatment	group	of	neuroprotective	agent	such	as	Vitamin	
B complex can be included as the standard treatment.
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